Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Cyclophosphamide monotherapy in children with Burkitt lymphoma: A study from the French-African Pediatric Oncology Group (GFAOP)
Pediatric Blood and Cancer, Volume 56, No. 1, Year 2011
Notification
URL copied to clipboard!
Description
Background: The French African Group of Pediatric Oncology was set-up to improve quality of care for children with cancer. Preliminary observations on the efficacy in Burkitt lymphoma (BL) of a cyclophosphamide monotherapy (CPM) have been published. We report the results of a multicentric prospective study combining first-line CPM and a multidrug second-line chemotherapy (SC) for refractory/relapsed patients. Procedure: Patients ≤18 years with Burkitt or Burkitt-like lymphoma, were included in six countries (Burkina-Faso, Cameroon, Ivory Coast, Madagascar, Mali, and Senegal). All patients received three weekly CPM courses (1.2 g/m2 IV with intrathecal methotrexate and hydrocortisone), stage 3/4 patients received three further courses. SC added methotrexate, vincristine, cytarabine, and prednisone. Results: There were 178 patients included (42 stage 1/2, 134 stage 3/4, and 2 unknown). Isolated facial localization was found in 41 patients, diffuse abdominal involvement in 120 patients including 65 with both. Nine early deaths were reported, toxicity occurred in 136/743 courses (83 patients) and was predominantly hematological. After CPM, complete remission (CR) rate was 47% with a 33% EFS. Because of rapid progression 76/108 eligible patients (85 primary refractory and 23 relapses) received SC resulting in 35.7% CR but a 21% toxic death rate. The OS of the whole strategy was 50.5% and correlated to stage. Conclusion: A prospective multicentric study on BL was feasible in very low-income countries. CPM can be recommended in stage 1-2 because of optimal cost/benefit ratio. However, more intensive strategies, still adapted to socio-economic conditions, are required for advanced stages 3 and 4. © 2010 Wiley-Liss, Inc.
Authors & Co-Authors
Traoré, Fousseyni Dicko
Mali, Bamako
Hopital Gabriel Toure
Coze, Carole M.
France, Marseille
Hopital la Timone
Atteby, Jean Jacques
Cote D'ivoire, Abidjan
Centre Hospitalier Universitaire de Treichville
Andre, Nicolas
France, Marseille
Hopital la Timone
Moreira, Claude
Senegal, Dakar
Centre Hospitalier Universitaire Aristide le Dantec de Dakar
Doumbé, Pierre
Cameroon, Yaounde
Centre Mere et Enfant de la Fondation
Ravelomanana, Noeline
Madagascar, Antananarivo
Hopital Mere Enfant de Tsaralalana
Ye, Diarra
Burkina Faso, Ouagadougou
Universitaire Yalgado-ouédraogo
Patte, Catherine
France, Villejuif
Institut de Cancerologie Gustave Roussy
Raquin, Marie Anne
France, Villejuif
Institut de Cancerologie Gustave Roussy
Raphaél, Martine M.
France, Le Kremlin-bicetre
Hopital de Bicetre
Lemerle, Jean S.
France, Villejuif
Institut de Cancerologie Gustave Roussy
Statistics
Citations: 63
Authors: 12
Affiliations: 9
Identifiers
Doi:
10.1002/pbc.22746
ISSN:
15455009
e-ISSN:
15455017
Research Areas
Cancer
Environmental
Maternal And Child Health
Study Design
Cohort Study
Study Locations
Cameroon
Ivory Coast
Madagascar
Mali
Senegal